A Study of Lasmiditan on the Heart in Healthy Participants
Status:
Completed
Trial end date:
2011-12-20
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine how two doses of lasmiditan affected the heart in
healthy participants. The study also evaluated how much lasmiditan got into the blood stream
and how long it took the body to get rid of it. Information about side effects was collected.
The study lasted a maximum of 46 days for each participant, not including screening.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
CoLucid Pharmaceuticals
Treatments:
Fluoroquinolones Lasmiditan Moxifloxacin Norgestimate, ethinyl estradiol drug combination